Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.49 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357751 | 0.93 | MOGAT2 (0.55) | MOGAT2MGAT2ERBB2EGFRIGF1R | |
| SCHEMBL5370195 | 0.91 | MOGAT2 (0.51) | MOGAT2MGAT2ERBB2EGFRIGF1R | |
| SCHEMBL5363509 | 0.89 | ERBB2 (0.49) | MOGAT2MGAT2ERBB2EGFRGSK3B | |
| SCHEMBL5369768 | 0.89 | MOGAT2 (0.51) | MOGAT2MGAT2ERBB2EGFRIGF1R | |
| SCHEMBL5365035 | 0.87 | ERBB2 (0.53) | ERBB2EGFRIGF1RGSK3BNOX4 | |
| SCHEMBL5374131 | 0.86 | MOGAT2 (0.51) | MOGAT2MGAT2GSK3BNOX4LRRK2 | |
| SCHEMBL5367175 | 0.86 | MOGAT2 (0.53) | MOGAT2MGAT2ERBB2EGFRIGF1R | |
| SCHEMBL5366907 | 0.85 | MOGAT2 (0.50) | MOGAT2MGAT2GSK3BPRKDCNOX4 | |
| SCHEMBL5367172 | 0.84 | ERBB2 (0.54) | MOGAT2MGAT2ERBB2EGFRIGF1R | |
| SCHEMBL5362515 | 0.84 | MOGAT2 (0.53) | MOGAT2MGAT2ERBB2EGFRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MOGAT2 1159/4885MGAT2 4714/4885ERBB2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.